Thematic evaluation
Back to company overview

Merck & Co., Inc. (MRK)

August 22, 2024

Compared to: AbbVie, Inc. (ABBV) | Pfizer Inc. (PFE) | Health Care Select Sector SPDR Fund (XLV)

Our reasoning

Merck & Co., Inc. (MRK) appears moderately undervalued based on its strong financial performance, robust pipeline, and leading market positions in key therapeutic areas. The company's above-average profitability metrics, solid growth prospects, and reasonable valuation multiples relative to peers suggest that the current stock price does not fully reflect MRK's long-term potential. However, pricing pressures and competition from generics/biosimilars present ongoing risks that temper the magnitude of undervaluation.

Key takeaways
  • Merck & Co., Inc. (MRK) is a diversified global healthcare company with a strong financial position, robust pipeline, and commitment to innovation.
  • The company has demonstrated strong revenue growth and profitability, driven by the success of its key products, particularly KEYTRUDA.
  • MRK's operational efficiency is high, as evidenced by its strong ROA and ROE, and its free cash flow generation is strong.
  • The company faces significant pricing pressures and competition from generics/biosimilars, as well as legal and regulatory risks.
  • MRK's valuation is generally in line with its peers, suggesting that the company is fairly valued.
  • The company's future outlook is positive, driven by its strong financial position, robust pipeline, and commitment to innovation.
  • Key factors to monitor include the company's ability to navigate pricing pressures and competition, its success in developing and commercializing new products, and its ability to manage legal and regulatory risks.
  • Overall, MRK presents an attractive investment opportunity for investors seeking exposure to the healthcare sector, but investors should be aware of the company's risks and potential headwinds.
Undervalued
Ask a question about Merck & Co., Inc. (MRK)
Evaluation summary

  1. Company Overview:

    • Merck & Co., Inc. (MRK) is a global healthcare company with a diversified business model focused on providing health solutions through prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.
    • The company operates in two main segments: Pharmaceutical (human health pharmaceutical and vaccine products) and Animal Health (veterinary pharmaceutical and vaccine products).
    • Key pharmaceutical products include Keytruda, Gardasil/Gardasil 9, Bridion, Prevymis, Januvia, and Janumet.
    • The Animal Health segment offers a wide range of veterinary pharmaceuticals, vaccines, and health management solutions.
    • MRK targets a broad range of customers, including patients, healthcare providers, governments, and other payers globally.
    • For comparative analysis, we will be using the Health Care Select Sector SPDR Fund (XLV) as a benchmark and AbbVie, Inc. (ABBV) and Pfizer Inc. (PFE) as industry peers.

  2. Financial Performance:

    • MRK has demonstrated strong revenue growth in recent quarters, driven by the success of its key products, particularly KEYTRUDA.
    • The company's profitability is also strong and increasing, driven by revenue growth and expanding margins.
    • MRK's gross profit margin, operating margin, and net profit margin are all significantly above the industry average, indicating strong pricing power and efficient cost management.
    • The company's return on assets (ROA), return on equity (ROE), and return on invested capital (ROIC) are also significantly above the industry average, indicating efficient utilization of assets and strong returns for shareholders.
    • Compared to its peers, MRK has consistently outperformed PFE in terms of financial performance, but it has underperformed ABBV.

  3. Operational Efficiency:

    • MRK's balance sheet analysis reveals a strong liquidity position, with a current ratio and quick ratio that are below the industry average but still indicate a strong ability to meet short-term obligations.
    • The company's strong operating cash flow generation provides ample short-term liquidity.
    • MRK's solvency is also strong, with a debt-to-equity ratio and debt-to-EBITDA ratio that are significantly below the industry average, indicating a conservative capital structure and strong financial stability.
    • The company's low level of financial leverage suggests that it is not taking on excessive debt and has a strong ability to service its debt obligations.
    • MRK's operational efficiency is high, as evidenced by its strong ROA and ROE.
    • The company's ability to expand its margins while controlling expenses indicates effective management of its operations.
    • MRK's free cash flow generation is strong, providing ample capacity for debt repayment, dividend growth, and investment in organic growth opportunities.
    • The company's capital expenditures have been decreasing, suggesting a shift in focus towards acquisitions and organic growth.
    • Compared to its peers, MRK has a lower risk profile than both ABBV and PFE, as indicated by its lower volatility and smaller maximum drawdown. However, ABBV has consistently offered better risk-adjusted returns, as indicated by its higher Sharpe ratio.

  4. Growth Opportunities:

    • MRK is actively expanding its pipeline and capabilities through strategic acquisitions and collaborations, which has resulted in a robust late-stage development portfolio.
    • The company is focused on expanding its presence in key therapeutic areas like oncology, vaccines, and hospital acute care, as well as its animal health business.
    • MRK is also exploring geographic expansion opportunities in emerging markets with high growth potential.
    • The company's capital allocation strategy is focused on investing in R&D, acquisitions, and organic growth opportunities.
    • Management has demonstrated a track record of successfully executing strategic plans, as evidenced by the company's strong financial performance and pipeline progress.

  5. Risks and Threats:

    • MRK faces significant pricing pressures and competition from generics/biosimilars that could impact sales and profitability of key products.
    • The company is also exposed to various legal and regulatory risks, including product liability lawsuits, antitrust litigation, and patent litigation.
    • MRK's dependence on patent protection and its ability to successfully develop and commercialize new products are key risk factors.
    • The company's reliance on third-party relationships and its ability to manage global operations effectively are also potential risks.
    • The industry is subject to ongoing regulatory changes, which could impact MRK's operations and profitability.

  6. Valuation Analysis:

    • MRK's valuation metrics, such as P/E ratio and EV/EBITDA, are generally in line with its peers, suggesting that the company is fairly valued.
    • The company's strong financial performance, robust pipeline, and commitment to innovation are potential catalysts for future growth.
    • However, the potential for generic/biosimilar competition and regulatory changes could create headwinds for the company's valuation.

  7. Price Performance:

    • MRK has outperformed XLV over the long term (2 and 3 years), but has underperformed in the shorter term (YTD, 1 week, 1 month, 3 months, 6 months, and 1 year). This suggests that MRK may be a more volatile stock with a higher risk profile.
    • MRK's performance relative to XLV has been inconsistent, with periods of both outperformance and underperformance.
    • Compared to its peers, MRK has generally underperformed ABBV over the past three years, particularly in the short-term periods. However, MRK has consistently outperformed PFE, especially in the longer-term periods. This suggests that MRK may be a more suitable investment for investors with a longer-term horizon.

  8. Future Outlook:

    • MRK's future outlook is positive, driven by its strong financial position, robust pipeline, and commitment to innovation.
    • The company's strong revenue growth and profitability are expected to continue, driven by the continued success of KEYTRUDA and the launch of new products.
    • The company's free cash flow is expected to remain robust, providing ample capacity for debt repayment, dividend growth, and investment in organic growth opportunities.
    • Analyst estimates for MRK's future performance are generally positive, with consensus expectations for continued revenue growth and profitability.

  9. Summary:

    • MRK is a diversified global healthcare company with a strong financial position, robust pipeline, and commitment to innovation.
    • The company has demonstrated strong revenue growth and profitability, driven by the success of its key products, particularly KEYTRUDA.
    • MRK's operational efficiency is high, as evidenced by its strong ROA and ROE, and its free cash flow generation is strong.
    • The company faces significant pricing pressures and competition from generics/biosimilars, as well as legal and regulatory risks.
    • MRK's valuation is generally in line with its peers, suggesting that the company is fairly valued.
    • The company's future outlook is positive, driven by its strong financial position, robust pipeline, and commitment to innovation.
    • Key factors to monitor include the company's ability to navigate pricing pressures and competition, its success in developing and commercializing new products, and its ability to manage legal and regulatory risks.
    • Overall, MRK presents an attractive investment opportunity for investors seeking exposure to the healthcare sector, but investors should be aware of the company's risks and potential headwinds.
Peer fundamentals 
Fundamentals
Insights
  • Merck is a diversified global healthcare company with leading positions in key therapeutic areas like oncology, vaccines, and hospital acute care, as well as a strong animal health business.
  • The company is actively expanding its pipeline and capabilities through strategic acquisitions and collaborations, which has resulted in a robust late-stage development portfolio.
  • Merck is demonstrating strong revenue growth and profitability, driven by the success of its key products, particularly KEYTRUDA.
  • The company's financial position is strong, with a conservative capital structure, ample liquidity, and robust free cash flow generation.
  • The company's future outlook is positive, driven by its strong financial position, robust pipeline, and commitment to innovation.
  • Key risks include dependence on patent protection, pricing pressures, competition from generics/biosimilars, reliance on third-party relationships, and exposure to legal proceedings and regulatory changes.
Analysis
  • Revenue - Merck's revenue growth has been consistently strong, driven by the success of its key products, particularly KEYTRUDA. - The company's revenue growth is expected to continue in the coming quarters, driven by the continued success of KEYTRUDA and the launch of new products. - The company's revenue growth is significantly above the industry average, indicating a strong market position and competitive advantage.
    • Profitability
      • Merck's profitability is strong and increasing, driven by revenue growth and expanding margins.
      • The company's gross profit margin, operating margin, and net profit margin are all significantly above the industry average, indicating strong pricing power and efficient cost management.
      • The company's return on assets and return on equity are also significantly above the industry average, indicating efficient utilization of assets and strong returns for shareholders.
    • Liquidity
      • Merck's liquidity position is strong, with a current ratio and quick ratio that are below the industry average but still indicate a strong ability to meet short-term obligations.
      • The company's strong operating cash flow generation provides ample short-term liquidity.
    • Solvency
      • Merck's solvency is strong, with a debt-to-equity ratio and debt-to-EBITDA ratio that are significantly below the industry average, indicating a conservative capital structure and strong financial stability.
      • The company's low level of financial leverage suggests that it is not taking on excessive debt and has a strong ability to service its debt obligations.
    • Operational Efficiency
      • Merck's operational efficiency is high, as evidenced by its strong return on assets and return on equity.
      • The company's ability to expand its margins while controlling expenses indicates effective management of its operations.
    • Cash Flow Analysis
      • Merck's cash flow from operations has been increasing, driven by strong earnings and effective working capital management.
      • The company's free cash flow generation is strong, providing ample capacity for debt repayment, dividend growth, and investment in organic growth opportunities.
      • The company's capital expenditures have been decreasing, suggesting a shift in focus towards acquisitions and organic growth.
    • Risk Factors
      • The company faces significant pricing pressures and competition from generics/biosimilars that could impact sales and profitability of key products.
      • The company is also exposed to various legal and regulatory risks, including product liability lawsuits, antitrust litigation, and patent litigation.
      • The company's dependence on patent protection and its ability to successfully develop and commercialize new products are key risk factors.
    • Future Outlook
      • Merck's future outlook is positive, driven by its strong financial position, robust pipeline, and commitment to innovation.
      • The company's strong revenue growth and profitability are expected to continue, driven by the continued success of KEYTRUDA and the launch of new products.
      • The company's free cash flow is expected to remain robust, providing ample capacity for debt repayment, dividend growth, and investment in organic growth opportunities.
Most recent earnings report
Financial statements 
All public filings
Comparative Analysis
Benchmarks (as of 2024-08-08)
Health Care Select Sector SPDR Fund (XLV)
  • Performance Comparison:
    • MRK has outperformed XLV over the long term (2 and 3 years), but has underperformed in the shorter term (YTD, 1 week, 1 month, 3 months, 6 months, and 1 year). This suggests that MRK may be a more volatile stock with a higher risk profile.
    • MRK's performance relative to XLV has been inconsistent, with periods of both outperformance and underperformance.
  • Risk and Return Analysis:
    • MRK has provided higher annualized returns than XLV over the 2 and 3-year periods, but has underperformed in the 1-year period. This suggests that MRK may be a more volatile stock with a higher risk profile.
    • MRK's annualized volatility has been consistently higher than XLV's, indicating a higher risk profile.
    • MRK's maximum drawdown of 20.17% is significantly higher than XLV's maximum drawdown of 16.06%, indicating that MRK is more susceptible to significant price declines.
  • Risk-Adjusted Performance:
    • XLV consistently shows a higher Sharpe ratio than MRK, indicating better risk-adjusted returns over the period. This suggests that XLV may be a more efficient investment than MRK.
    • MRK's beta values have generally been lower than XLV's, indicating a lower sensitivity to market movements. This suggests that MRK may be a less risky investment than XLV.
  • Overall Assessment:
    • MRK has shown strong long-term performance, but has been more volatile and has experienced larger drawdowns than XLV. This suggests that MRK may be a more risky investment than XLV.
    • XLV has consistently shown better risk-adjusted returns than MRK, indicating that it may be a more efficient investment.
    • Investors seeking higher potential returns may consider MRK, but should be aware of its higher risk profile. Investors seeking a more stable and less risky investment may prefer XLV.
Peers Price History(as of 2024-08-08)
AbbVie, Inc. (ABBV)Pfizer Inc. (PFE)
  • Performance Comparison:
    • MRK has generally underperformed ABBV over the past three years, particularly in the short-term periods (YTD, 1 Week, 1 Month, 3 Months, and 6 Months). However, MRK has consistently outperformed PFE, especially in the longer-term periods (1 Year, 2 Years, and 3 Years). This suggests that MRK may be a more suitable investment for investors with a longer-term horizon.
    • MRK's performance has been more consistent relative to PFE, while its performance relative to ABBV has been more volatile.
  • Risk and Return Analysis:
    • MRK has provided lower annualized returns than ABBV over the past three years. However, MRK has provided higher annualized returns than PFE.
    • MRK has been less volatile than both ABBV and PFE, as indicated by its lower annualized volatility.
    • MRK has experienced a smaller maximum drawdown than ABBV and PFE, suggesting a lower risk profile.
  • Risk-Adjusted Performance:
    • MRK has a moderate Sharpe ratio, indicating a reasonable risk-adjusted return. However, ABBV has consistently had a higher Sharpe ratio, suggesting better risk-adjusted returns. PFE has had a lower Sharpe ratio, indicating less favorable risk-adjusted returns.
    • MRK's beta value is below 1, suggesting that it is less sensitive to market movements than the overall market. However, PFE's beta value is higher than MRK's, indicating that it is more sensitive to market movements.
  • Overall Assessment:
    • MRK has consistently outperformed PFE in terms of performance, but it has underperformed ABBV. MRK has a lower risk profile than both ABBV and PFE, as indicated by its lower volatility and smaller maximum drawdown. However, ABBV has consistently offered better risk-adjusted returns, as indicated by its higher Sharpe ratio.
    • MRK's lower volatility and smaller maximum drawdown make it a potentially attractive investment for investors seeking lower risk. However, ABBV's higher Sharpe ratio suggests that it may be a more suitable investment for investors seeking higher risk-adjusted returns.
    • The recent trends in volatility and Sharpe ratio suggest that the market is becoming more uncertain, and investors are becoming more cautious. This may lead to increased volatility and lower returns for all three companies.
Peers Fundamentals(as of 2024-06-30)
AbbVie, Inc. (ABBV)Pfizer Inc. (PFE)

  1. Market Position and Size:

    • MRK is a large pharmaceutical company with a market capitalization of 288766.0, placing it between its peers, AbbVie, Inc. (ABBV) with a market cap of 336311.0 and Pfizer Inc. (PFE) with a market cap of 162974.0.
    • Despite having a smaller market cap than ABBV, MRK generates higher revenue and EBITDA, indicating a strong financial performance and competitive position.

  2. Profitability and Efficiency:

    • MRK significantly outperforms its peers and industry averages in profitability metrics, with a high Gross Profit Margin, EBITDA Margin, and Net Profit Margin. This suggests strong pricing power, cost control, and overall financial strength.
    • MRK also demonstrates high efficiency in generating returns from its assets, capital, and investments, as evidenced by its high ROA, ROTE, ROTC, and ROIC. This indicates effective asset utilization, capital allocation, and strong profitability.

  3. Financial Health and Stability:

    • MRK's liquidity and solvency metrics are moderate compared to its peers and industry averages. Its current and quick ratios indicate a moderate level of liquidity, while its debt ratios suggest a relatively conservative debt structure.
    • MRK's strong cash flow generation, with high net operating cash flow and substantial free cash flow, demonstrates its financial health and potential for shareholder returns.

  4. Valuation and Market Perception:

    • MRK's valuation metrics are attractive compared to its peers and industry averages. Its lower EV/Sales, EV/EBITDA, P/E, P/B, and P/S ratios suggest that the market perceives MRK as relatively undervalued, potentially presenting an opportunity for investors.

  5. Cash Flow and Capital Management:

    • MRK generates substantial free cash flow after accounting for capital expenditures, indicating strong financial health and potential for shareholder returns.
    • MRK's significant capital expenditure suggests that it is investing heavily in its business, potentially indicating growth opportunities and expansion plans.

  6. Growth and Future Prospects:

    • MRK exhibits strong growth in profitability and cash flow metrics, suggesting that it is effectively capitalizing on market opportunities and executing its strategic initiatives.
    • While MRK's revenue growth is moderate, its profit growth is significantly higher, indicating strong operational efficiency and pricing power.
    • MRK's growth in profitability and cash flow metrics is accelerating, suggesting a positive outlook for future growth and shareholder returns.

  7. Potential for Investment:

    • MRK presents an attractive investment opportunity due to its strong profitability, efficient returns generation, robust cash flow generation, and conservative debt structure.
    • Its attractive valuation metrics, compared to its peers and industry averages, further enhance its investment appeal.

  8. Key Risks and Considerations:

    • MRK's moderate revenue growth and relatively weaker liquidity position compared to the industry average could pose potential risks.
    • The company's inconsistent growth in assets and book value per share suggests potential areas for improvement in asset management and capital allocation.

  9. Overall Assessment:

    • MRK is a financially strong and well-positioned pharmaceutical company with a strong track record of profitability, efficiency, and cash flow generation.
    • Its attractive valuation and accelerating growth in profitability and cash flow metrics suggest a positive outlook for future growth and shareholder returns.
    • While its revenue growth is moderate and its liquidity position is relatively weaker, its overall financial performance and growth trajectory indicate a strong potential for continued success.